3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 3
2
Phase 1/2
1
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
CNS
2
Conditions
Carcinoma, Non-Small-Cell Lung
9
Lung Neoplasms
2
Brain Neoplasms
2
Non-squamous Non-small Cell Lung Cancer
1
Neoplasms
1
Adenocarcinoma
1
Interventions
Radiosurgery
23
Radiotherapy
20
Temozolomide
17
Lomustine
9
Bevacizumab
8
Surgical Procedures, Operative
7
Procarbazine
6
Vincristine
5
Nivolumab
5
Memantine
5
Magnetic Resonance Spectroscopy
4
Filgrastim
4
Etoposide
4
Cisplatin
4
Carboplatin
4
Specimen Handling
3
Sodium Chloride
3
Radiation
3
Methylphenidate
3
Mental Status and Dementia Tests
3
Granulocyte Colony-Stimulating Factor
3
Gefitinib
3
Cyclophosphamide
3
Corticotropin-Releasing Hormone
3
Carmustine
3
icotinib
2
etoposide phosphate
2
efaproxiral
2
X-Rays
2
Tranexamic Acid
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Brain Neoplasms
×
icotinib
×
Clear all
NCT04058704
2019-08-15
SMART
Betta Pharmaceuticals Co., Ltd.
Phase 3
Unknown
296 enrolled
NCT01724801
2017-03-01
BRAIN
Guangdong Association of Clinical Trials
Phase 3
Completed
176 enrolled